Subscribe | API Access |

OncoTherapy Science,Inc. (4564.T) Growth Market

All TDNet disclosures translated to English by Pulse News Wire.

Disclosures

Feb 6, 2026 — Mar 6, 2026

Date Range

GROWTH

Market Segment

Pharmaceutical

Sector

Disclosures

Date	Type	Headline	PDF
Mar 6	Equity Issuance	OncoTherapy Science Requests Suspension of Exercise for Warrant Issue No. 38	PDF
Feb 6	Equity Issuance	OncoTherapy Science Reports Q3 Non-operating Expenses	PDF
Feb 6	Earnings	Oncotherapy Science,Inc. Reports Q3 Revenue of 597 million, Up 6%	PDF

Disclosure Types

Equity Issuance: 2 Earnings: 1

Frequently Asked Questions

Where can I read OncoTherapy Science,Inc.'s disclosures in English?

Pulse News Wire translates all TDNet filings for OncoTherapy Science,Inc. (4564.T) to English. 3 disclosures have been translated since Feb 6, 2026.

How many disclosures has OncoTherapy Science,Inc. filed on TDNet?

Pulse News Wire has translated 3 disclosures for OncoTherapy Science,Inc. since Feb 6, 2026.

Does OncoTherapy Science,Inc. publish English IR materials?

No. OncoTherapy Science,Inc. is listed on the GROWTH Market and has no English disclosure requirement. Pulse News Wire is the only English-language source for these filings.

What types of disclosures has OncoTherapy Science,Inc. filed?

OncoTherapy Science,Inc. has filed the following types of disclosures on TDNet: Equity Issuance (2), Earnings (1).

English translations for all 4,436 JPX-listed companies.

Including the 2,300 Standard and Growth Market companies with no other English source.

See Pricing Browse Articles